Skip to main content
. 2015 Jul 3;31(1):22–29. doi: 10.1007/s11606-015-3452-x

Table 3.

Measures of Management of Chronic Kidney Disease by Prior Contact with a Nephrologist Over Three Ranges of Estimated Glomerula Filtration Rate

eGFR 15– < 30 ml/min/1.73 m2 eGFR 30– < 60 ml/min/1.73 m2 eGFR ≥ 60 ml/min/1.73 m2
Prior Contact with Nephrologist
Variables Yes (n = 705) No (n = 87) Yes (n = 1597) No (n = 778) Yes (n = 289) No (n = 399)
Systolic BP, mm Hg 133 (24) 133 (22) 128 (22) 130 (23) 121 (18) 122 (19)
 At goal (< 130/80 mm Hg) 48 % (337/705) 45 % (39/87) 57 % (908/1596) 53 % (410/778) 74 % (213/289) 72 % (289/399)
 Treateda and at goal 48 % (324/681) 47 % (39/83) 56 % (848/1511) 53 % (386/734) 71 % (167/235) 66 %(178/271)
Bicarbonate, mEq/L 23 (3) 23 (4) 24 (3)* 25 (3)* 26 (3) 26 (3)
 At goal (≥ 22 mEq/L) 64 % (451/698) 63 % (55/87) 84 % (1340/1585) 86 % (669/773) 91 % (262/281) 94 % (376/397)
 Treatedb and at goal 65 % (26/40)* 0* 73 % (16/22) 50 % (2/4) 50 % (1/2) 0
Phosphate, mg/dL 4.1 (1) 4.2 (1) 3.7 (1) 3.7 (1) 3.4 (1)* 3.5 (1)*
 At goal (2.7–4.6 mg/dL) 75 % (530/687) 71 % (62/87) 89 % (1423/1574) 90 % (697/766) - -
 Treatedc and at goal 75 % (64/85)* 46 % (5/11)* 88 % (87/99) 79 % (33/42) - -
iPTH 109 (67–176) 92 (61–159) 55 (36–84) 49 (33–74) 36 (28–51) 35 (27–47)
 At goale (not on treatment) 24 % (136/564)* 37 % (28/75)* 39 % (572/1458) 43 % (317/736) - -
 Treatedd and at goale 53 % (75/141) 58 % (7/12) 48 % (66/139) 62 % (26/42) - -
Hemoglobin, g/dl 11.7 (1.7) 11.5 (1.6) 12.7 (1.7)* 12.5 (1.7)* 13.9 (1.6)* 13.4 (1.5)*
 At goal (11–12 g/dl, not on treatment) 91 % (480/528)* 85 % (66/78)* 96 % (1366/1422) 95 % (689/729) 97 % (267/275) 98 % (370/377)
 Treatedf and at goal 57 % (100/177) 67 % (6/9) 49 % (86/175) 39 % (19/49) 21 % (3/14) 41 % (9/22)
ACEi or ARB use 67 % (473/702) 74 % (64/87) 76 % (1199/1585)* 71 % (550/771)* 60 % (173/287)* 46 % (181/396)*

Values are expressed as mean (standard deviation), median (interquartile range), or % (numerator/denominator). For systolic BP, bicarbonate and phosphate, the “at goal” category includes individuals with and without treatment

ACEi angiotensin converting enzyme inhibitor; ARB angiotensin receptor blocker; BP blood pressure; iPTH intact parathyroid hormone

aUse of any antihypertensive medication

bUse of sodium bicarbonate, potassium bicarbonate or sodium citrate

cUse of any phosphorus binder

dUse of a phosphorus binder, active vitamin D formulation or cinacalcet

eiPTH (pg/ml) treatment goal based on eGFR: 70–110 (eGFR 15–30); 30–59 (eGFR 30–60)

fUse of an erythropoietin stimulating agent or iron

*p < 0.05